Marksans Pharma Reappoints Mark Saldanha as MD, Reinforces Strategic Continuity

Leadership Renewal and Tenure Details

Marksans Pharma Ltd has reappointed Mark Saldanha as Managing Director for a fresh five-year term, effective October 6, 2025, pending shareholder approval at the upcoming AGM.

• The decision was finalized by the Board on July 25, 2025
• Saldanha’s DIN is 00020983; he is also related to Director Sandra Saldanha
• His reappointment ensures leadership continuity amid global expansion

Experience and Strategic Significance

• Saldanha brings over 24 years of expertise in production, marketing, and finance
• He is credited with transforming Marksans into a global pharmaceutical player
• His leadership is expected to drive innovation and strengthen market positioning

Forward-Looking Vision

• The company aims to deepen its footprint in regulated markets
• Focus areas include R&D, specialty generics, and operational efficiency
• The reappointment signals investor confidence and long-term growth intent

Sources: Moneycontrol Hindi, Marksans Pharma Website, Rediff MoneyWiz